ATN International, Inc.ATNINASDAQ

52-Week Range14-30

13.76Current 26.4330.45

Want to monitor ATNI?

Get notified when price crosses targets, volume spikes, or RSI hits oversold

Gross Margin

Operating Margin

Revenue Growth

atlantic tele-network, inc.

Michael Prior

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance

Alerts

News

uniQure N.V. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - QURE

Kyndryl Holdings, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - KD

MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit with the Schall Law Firm

Driven Brands Holdings Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - DRVN

Eos Energy Enterprises, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - EOSE

Plug Power Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - PLUG

InterContinental Hotels Group PLC Announces Transaction in Own Shares - March 20

Hellman's mayonnaise maker Unilever in takeover talks with McCormick for food business

PLUG Investors Have Opportunity to Lead Plug Power Inc. Securities Fraud Lawsuit with the Schall Law Firm

SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

McCormick Issues Statement

Serbia secures US sanctions waiver for its NIS oil firm, energy minister says

Notice of Full Year Results and Investor Presentation

Morningstar Awards for Investing Excellence UK 2026: Winners Announced

Apollo Global Management, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - APO

Prediction: This Will Be Amazon's Stock Price in 5 Years

The Iran war is sending shockwaves through the world's busiest IPO market

Novartis to Buy Breast-Cancer Drug From Synnovation for Up to $3 Billion

Transaction in Own Shares

The 15-20 National Hospital and GenSight Biologics Announce the First Treatments in the French Named Patient Early Access Program (AAC) for GS010/LUMEVOQ®

About